Acquired mutations in ASXL1 in acute myeloid leukemia: prevalence and prognostic value

Somatic mutations in the additional sex comb-like 1 (ASXL1) gene have been described in various types of myeloid malignancies, including acute myeloid leukemia. Analysis of novel markers, such as ASXL1 mutations, in independent clinical trials is indispensable before considering them for clinical decision-making. We analyzed 882 well-characterized acute myeloid leukemia cases to determine the prevalence and prognostic impact of ASXL1 exon12 mutations. Truncating ASXL1 mutations were present in 46 cases (5.3%). ASXL1 mutations were inversely associated with FLT3 internal tandem duplications and mutually exclusive with NPM1 mutations. ASXL1 mutations were an unfavorable prognostic factor as regards survival (median overall survival 15.9 months vs. 22.3 months; P=0.019), with a significantly lower complete response rate (61% vs. 79.6%; P=0.004). In multivariate analyses, ASXL1 mutations were independently associated with inferior poor overall survival (HR 1.52, P=0.032). In conclusion, ASXL1 mutations are common mutations in acute myeloid leukemia and indicate a poor therapy outcome.

• Publication year

  2012

• Venue

  Haematologica

• Publication date

  2012-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.3324/haematol.2011.051532PMID 22058207PMCID PMC3291593
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Cytarabine dose for acute myeloid leukemia.

  2011cited by this paper
• Cytarabine dose for acute myeloid leukemia.

  2011cited by this paper
• The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration

  2010cited by this paper
• Loss-of-function Additional sex combs like 1 mutations disrupt hematopoiesis but do not cause severe myelodysplasia or leukemia.

  2010cited by this paper
• Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.

  2010cited by this paper
• High EVI1 expression predicts outcome in younger adult patients with acute myeloid leukemia and is associated with distinct cytogenetic abnormalities.

  2010influential reference
• Frequent mutation of the polycomb-associated gene ASXL1 in the myelodysplastic syndromes and in acute myeloid leukemia

  2010cited by this paper
• ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

  2010influential reference
• Mutations of ASXL1 gene in myeloproliferative neoplasms

  2009influential reference
• Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia

  2009cited by this paper
• Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family.

  2006cited by this paper
• Mutations in nucleophosmin (NPM1) in acute myeloid leukemia (AML): association with other gene abnormalities and previously established gene expression signatures and their favorable prognostic significance.

  2005influential reference
• The value of fludarabine in addition to ARA-C and G-CSF in the treatment of patients with high-risk myelodysplastic syndromes and AML in elderly patients.

  2004cited by this paper
• Second hit mutations in the RTK/RAS signaling pathway in acute myeloid leukemia with inv(16).

  2004cited by this paper
• Incidence and prognosis of c‐KIT and FLT3 mutations in core binding factor (CBF) acute myeloid leukaemias

  2003cited by this paper
• Effect of priming with granulocyte colony-stimulating factor on the outcome of chemotherapy for acute myeloid leukemia.

  2003cited by this paper
• A human homolog of Additional sex combs, ADDITIONAL SEX COMBS-LIKE 1, maps to chromosome 20q11.

  2003influential reference
• Value of different modalities of granulocyte-macrophage colony-stimulating factor applied during or after induction therapy of acute myeloid leukemia.

  1997cited by this paper
• Clinical Trials and Observations

  year unknowncited by this paper

• Mutant ASXL1 Drives Transcriptional Activation and Repression in Human Hematopoiesis

  2026influential citation
• Low-VAF TP53-Mutated AML Displays Distinct Biological Features in a Single-Center Cohort

  2026cites this paper
• Molecular genetic characterization of mixed-phenotype acute leukemia (MPAL) with BCR::ABL1 fusion.

  2025cites this paper
• Correlation between epigenetic modifier gene mutations and prognosis of patients with acute lymphoblastic leukemia: a systematic review and meta-analysis.

  2025cites this paper
• Molecular abnormalities and clinical features in adult patients with acute myeloid leukemia in Thailand

  2025cites this paper
• Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report

  2025cites this paper
• Genetic profile of ASXL1 gene in risk assessment in acute myeloid leukemia

  2025cites this paper
• ASXL1 MUTATIONAL ANALYSIS IN MYELOFIBROSIS PATIENTS IN KHYBER PAKHTUNKHWA

  2025cites this paper
• Novel Mutations in Acute Erythroid Leukemia–A Case Report with Review of Literature

  2024cites this paper
• Generation and Characterization of Induced Pluripotent Stem Cells Carrying An ASXL1 Mutation

  2024cites this paper
• Prognostic significance of ASXL1 mutations in acute myeloid leukemia: A systematic review and meta-analysis

  2024cites this paper
• Targeting BIRC5 as a Therapeutic Approach to Overcome ASXL1-associated Decitabine Resistance.

  2024cites this paper
• A comparative analysis of the clinical and genetic profiles of blast phase BCR::ABL1‐negative myeloproliferative neoplasm and acute myeloid leukemia, myelodysplasia‐related

  2024cites this paper
• The role of ASXL1 mutations and ASXL1 CircRNAs in cancer

  2024cites this paper
• Pathophysiology of Acute Myeloid Leukemia

  2024cites this paper
• Rapid clonal selection within early hematopoietic cell compartments presages outcome to ivosidenib combination therapy

  2024cites this paper
• Acute myeloid leukemia and myelodysplastic neoplasms: clinical implications of myelodysplasia-related genes mutations and TP53 aberrations

  2024cites this paper
• Comprehensive genomic characterization of hematologic malignancies at a pediatric tertiary care center

  2024cites this paper
• ASXL1 truncating variants in BOS and myeloid leukemia drive shared disruption of Wnt-signaling pathways but have differential isoform usage of RUNX3

  2024cites this paper
• Cytogenetic and Molecular Characteristics in Adult Hispanic Acute Myeloid Leukemia Patients From Puerto Rico

  2024cites this paper
• Comparative Analysis of AML Classification Systems: Evaluating the WHO, ICC, and ELN Frameworks and Their Distinctions

  2024cites this paper
• Prognosis and treatment in acute myeloid leukemia: a comprehensive review

  2024cites this paper
• Myeloid sarcoma with NPM1 mutation may be clinically and genetically distinct from AML with NPM1 mutation: a study from the Bone Marrow Pathology Group

  2023cites this paper
• Effects of Black Raspberry Supplementation on Methylation Pathways in Vav-cre Asxl1fl/fl Tet2fl/fl Double Knockout Mice with Early-stage Myelodysplastic Syndrome

  2023cites this paper
• Expression of interferon regulatory factor family and its prognostic value in acute myeloid leukemia.

  2023cites this paper
• Clonal haematopoiesis - a novel entity that modifies pathological processes in elderly

  2023cites this paper
• Clonal hematopoiesis and acute myeloid leukemia

  2023cites this paper
• High molecular risk variants, severe thrombocytopenia and large unstained cells count affect the outcome in primary myelofibrosis

  2023cites this paper
• Modern Risk Stratification of Acute Myeloid Leukemia in 2023: Integrating Established and Emerging Prognostic Factors

  2023cites this paper
• Unsupervised meta-clustering identifies risk clusters in acute myeloid leukemia based on clinical and genetic profiles

  2023cites this paper
• Co-mutation of ASXL1 and SF3B1 Predicts Poorer Overall Survival Than Isolated ASXL1 or SF3B1 Mutations

  2023cites this paper
• Epigenetic regulation by ASXL1 in myeloid malignancies

  2023cites this paper
• Multiomics of Bohring-Opitz syndrome truncating ASXL1 mutations identify canonical and noncanonical Wnt signaling dysregulation

  2023cites this paper
• Biallelic TET2 mutations and canonical ASXL1 mutations are frequent and cooccur in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): An institutional experience and review of literature

  2023cites this paper
• Clonal Hematopoiesis as a pitfall in germline variant interpretation in the context of Mendelian disorders.

  2022cites this paper
• Multi-omics on truncating ASXL1 mutations in Bohring Opitz syndrome identify dysregulation of canonical and non-canonical Wnt signaling

  2022cites this paper
• Asxl1 deletion disrupts MYC and RNA polymerase II function in granulocyte progenitors

  2022cites this paper
• Modeling and predicting cancer clonal evolution with reinforcement learning

  2022cites this paper
• Role of Biomarkers in the Management of Acute Myeloid Leukemia

  2022cites this paper
• Essential thrombocythaemia progression to the fibrotic phase is associated with a decrease in JAK2 and PDL1 levels

  2022cites this paper
• JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome

  2022cites this paper
• Role of ASXL1 in Hematopoiesis and Myeloid Diseases.

  2022cites this paper
• PCR‐Fluo‐ASXL1‐FA: A fast, sensitive and inexpensive complementary method to detect ASXL1 mutations in haematological malignancies

  2022cites this paper
• Mutations in the miR-142 gene are not common in myeloproliferative neoplasms

  2022cites this paper
• Evaluating the frequency, prognosis and survival of RUNX1 and ASXL1 mutations in patients with acute myeloid leukaemia in northeastern Iran

  2022cites this paper
• Murine Models of Acute Myeloid Leukemia

  2022cites this paper
• The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing

  2022cites this paper
• Rapid progression of myelofibrosis in polycythemia vera patient carrying SRSF2 c.284C>A p.(Pro95His) and unique ASXL1 splice site c.1720‐2A>G variant

  2022cites this paper
• Recurrent mutations in the epigenetic regulator Additional Sex-Combs Like 1 ( ASXL 1 ) are associated with universally poor prognosis in myeloid malignancy

  2022cites this paper
• PD-L1 and JAK2 mRNA level in essential thrombocythaemia depends on the driver mutational status and the bone marrow fibrosis grade

  2022cites this paper
• Genomic characteristics and prognostic significance of co‐mutated ASXL1/SRSF2 acute myeloid leukemia

  2021cites this paper
• Loss of H3K27 methylation identifies poor outcomes in adult-onset acute leukemia

  2021cites this paper
• Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning

  2021cites this paper
• ASXL1 mutations with serum EPO levels predict poor response to darbepoetin alfa in lower-risk MDS: W-JHS MDS01 trial

  2021cites this paper
• Mitochondria and Their Relationship with Common Genetic Abnormalities in Hematologic Malignancies

  2021cites this paper
• Analysis of genetic variants in myeloproliferative neoplasms using a 22-gene next-generation sequencing panel

  2021cites this paper
• The ASXL1-G643W variant accelerates the development of CEBPA mutant acute myeloid leukemia

  2021cites this paper
• 3+7 Combined Chemotherapy for Acute Myeloid Leukemia: Is It Time to Say Goodbye?

  2021cites this paper
• Diagnosis and Classification of AML: WHO 2016

  2021cites this paper
• Prognostic Factors in AML

  2021cites this paper
• Extramedullary Clonal Hematopoiesis with Indeterminate Potential.

  2021cites this paper
• The Impact of Epigenetic Modifications in Myeloid Malignancies

  2021cites this paper
• Advances in therapeutic options for newly diagnosed, high-risk AML patients

  2021cites this paper
• Therapeutic Opportunities of Targeting Canonical and Noncanonical PcG/TrxG Functions in Acute Myeloid Leukemia.

  2021cites this paper
• Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study.

  2021cites this paper
• Genomic characterization of relapsed acute myeloid leukemia reveals novel putative therapeutic targets.

  2021cites this paper
• ASXL1 mutation as a surrogate marker in acute myeloid leukemia with myelodysplasia‐related changes and normal karyotype

  2020cites this paper
• Next-generation sequencing-based molecular genetic profiling in adults with acute myeloid leukaemia

  2020cites this paper
• Pathogenic Impacts of Dysregulated Polycomb Repressive Complex Function in Hematological Malignancies

  2020cites this paper
• Exploring chromatin organization and transcription in S. pombe and hematopoietic development

  2020cites this paper
• Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with ASXL1 mutations

  2020cites this paper
• ASXL1 Directs Neutrophilic Differentiation via Modulation of MYC and RNA Polymerase II

  2020cites this paper
• Prognostic impact of the ELN2017 risk classification in patients with AML receiving allogeneic transplantation.

  2020cites this paper
• Acute myeloid leukemia with myelodysplasia-related changes diagnosed with multilineage dysplasia alone demonstrates superior clinical outcome.

  2020cites this paper
• Dynamics of mutations in patients with essential thrombocythemia treated with imetelstat

  2020cites this paper
• Mutation profile and prognostic relevance in elderly patients with de novo acute myeloid leukemia treated with decitabine‐based chemotherapy

  2020cites this paper
• Biological Mechanisms and Clinical Significance of BAP1 Mutations in Human Cancer.

  2020cites this paper
• Bone marrow fibrosis, sequence variant of asxl1, and Sjögren syndrome: A case report

  2020cites this paper
• The molecular analysis of four coexistent mutations in additional sex combs like 1 (ASXL1) gene in a patient with acute myeloid leukemia

  2020cites this paper
• Prognostic role of SCAMP family in acute myeloid leukemia

  2020cites this paper
• The ASXL1-G643Wvariant accelerates the development of CEBPA mutant acute myeloid leukemia

  2020cites this paper
• The role of ASXL1 in hematopoiesis and myeloid malignancies

  2019cites this paper
• Mutations associated with a 17-gene leukemia stem cell score and the score’s prognostic relevance in the context of the European LeukemiaNet classification of acute myeloid leukemia

  2019cites this paper
• RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia

  2019cites this paper
• Exploiting genomic instability in Acute Myeloid Leukemia: when TP53 fails.

  2019cites this paper
• Impact of mutations in epigenetic modifiers in acute myeloid leukemia: A systematic review and meta-analysis

  2019cites this paper
• The interference of genetic associations in establishing the prognostic value of the immunophenotype in acute myeloid leukemia

  2018cites this paper
• Aberrant histone modifications induced by mutant ASXL1 in myeloid neoplasms

  2018cites this paper
• Clinical molecular testing for ASXL1 c.1934dupG p.Gly646fs mutation in hematologic neoplasms in the NGS era

  2018cites this paper
• Genetic alterations crossing the borders of distinct hematopoetic lineages and solid tumors: Diagnostic challenges in the era of high-throughput sequencing in hemato-oncology.

  2018cites this paper
• Genetic Landscape of Acute Myeloid Leukemia Interrogated by Next-generation Sequencing: A Large Cancer Center Experience.

  2018cites this paper
• Consequences of mutant TET2 on clonality and subclonal hierarchy

  2018cites this paper
• ASXL1 mutations in myeloid neoplasms: pathogenetic considerations, impact on clinical outcomes and survival

  2018cites this paper
• Neoplastische Bildungsstörungen der Hämatopoiese mit Ausreifungsverlust

  2018cites this paper
• Next generation sequencing to identify multiple clinically relevant genetic lesions for the diagnosis of acute myeloid leukaemia

  2018cites this paper
• 急性髓系白血病中组蛋白甲基化修饰调控异常及相关靶向治疗研究进展

  2018cites this paper
• Exploring the role of epigenetic alterations in myeloid malignancies with focus on drug response

  2018cites this paper
• Prognostic significance of ASXL1 mutation types and allele burden in myelofibrosis

  2018cites this paper
• Acute Myeloid Leukemia with Myelodysplasia-Related Changes, Therapy-Related Myeloid Neoplasms, and Acute Myeloid Leukemia, Not Otherwise Specified

  2018cites this paper
• ASXL1 mutations in AML are associated with specific clinical and cytogenetic characteristics

  2018cites this paper